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Introduction
============

VEGF is an important mediator of cell survival, proliferation and angiogenesis (Ferrara, [@b12]; Shibuya, [@b27]; Musumeci *et al*., [@b24]). It constitutes a family of mammalian homodimeric glycoproteins, comprising VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor. VEGF-A is an important and potent mediator of tumour-induced angiogenesis (Ferrara, 2004; 2009[@b11],[@b12]). VEGF family members bind to three different VEGF receptors (VEGFR1, VEGFR2 and VEGFR3) with differing selectivity profiles (Ferrara, [@b12]; Shibuya, [@b27]). VEGFR2 is the major regulator of VEGF-driven responses in vascular endothelial cells including permeability, proliferation, invasion and migration. It is also considered to be a crucial mediator of angiogenesis (Ferrara, [@b12]; Shibuya, [@b27]). Its signalling pathways are relatively well understood with tyrosine residues Y1175 and Y1214 in the human VEGFR2 being the main auto-phosphorylation sites activated by VEGF binding and tyrosine kinase activation. This creates binding sites for key intracellular signalling proteins such as Grb2, PLCγ and Shc1 (Matsumoto and Mugishima, [@b23]; Rososki, [@b26]; Koch *et al*., [@b18]).

The transmembrane glycoprotein neuropilin 1 forms a complex with VEGFR2 and acts as a co-receptor to enhance VEGF-A binding, mediate focal adhesion kinase phosphorylation and increase cell migration (Herzog *et al*., [@b15]). It has also been shown to promote VEGFR2 internalization and endosomal trafficking, leading to the regulation of ERK signalling and cell proliferation (Lanahan *et al*., [@b19]). Neuropilin 1 is engaged by specific VEGF isoforms and has recently been the target of drug discovery efforts to design low MW inhibitors of neuropilin 1 (Djordjevic and Driscoll, [@b8]). Multiple isoforms of VEGF-A, ranging from 121 to 206 amino acids, can be generated by alternative exon splicing that differ in their ability to bind heparin (affecting bioavailability) or neuropilin 1 and they appear to play distinctive roles in angiogenesis (Woolard *et al*., 2004; 2009[@b30],[@b31]; Ferrara, [@b12]). For example, alternative splicing in exon 8 of the VEGF gene can generate VEGF~xxx~a and VEGF~xxx~b (where xxx is the amino acid length) isoforms that have been reported to have pro-angiogenic and anti-angiogenic activities respectively (Woolard *et al*., 2004; 2009[@b30],[@b31]). In keeping with this, VEGF~165~b has been reported to be a weak partial agonist at VEGFR2, able to bind weakly to heparin and does not interact with neuropilin-1 (Cebe Suarez *et al*., [@b6]; Catena *et al*., [@b5]).

Receptor tyrosine kinases inhibitors (RTKIs) targeted at VEGFR2 have proved to be attractive approaches to cancer therapy based on their ability to reduce angiogenesis and/or lymph-angiogenesis (Musumeci *et al*., [@b24]). There are three known classes of RKTIs. Class I RTKIs, such as cediranib, vandetanib and pazopanib, are able to bind to the active conformation of the receptor and compete for the intracellular ATP-binding site within the catalytic domain of VEGFR2 (Gotink and Verheul, [@b14]; Davis *et al*., [@b7]; Blasi *et al*., [@b4]). Class II RTKIs, such as sorafenib, bind to the non-active conformation of the receptor at the hydrophobic pocket of the activation loop and inhibit kinase activity by indirectly preventing the binding of ATP (Gotink and Verheul, [@b14]; Davis *et al*., [@b7]). Finally, class III RTKIs such as neratinib, covalently bind to cysteine residues within the intracellular ATP-binding region of the receptor (Gotink and Verheul, [@b14]; Davis *et al*., [@b7]). Most of these small molecule RTKIs interact with multiple members of the PK family (Davis *et al*., [@b7]). For example, binding studies with purified kinase domains have shown that vandetanib is a more potent inhibitor of Abl1 (16 nM), EGFR (9.5 nM), MEK5 (49 nM) than VEGFR2 (820 nM) (Davis *et al*., [@b7]).

Quantitative evaluation of the interactions of RTKIs with VEGFR2 in living cells has, however, been largely lacking. This is important as, by definition, all RTKIs need to access the intracellular regions of VEGFR2 in order to elicit their pharmacological action. It is therefore vital to understand how the different RTKIs affect VEGF~165~a- and VEGF~165~b-mediated signalling in intact cells. The aim of the present study was to undertake a quantitative pharmacological analysis of the effect of VEGF~165~ isoforms and RTKIs on VEGFR2-mediated signalling in living cells. An important signalling pathway for VEGFR2 is the calcineurin-nuclear factor of activated T-cells (NFAT) system that, following activation by VEGF, leads to nuclear translocation of the NFAT transcription factor and expression of pro-angiogenic and pro-inflammatory genes (Suehiro *et al*., [@b28]; Yang *et al*., [@b32]). Reporter gene systems have been used extensively to study GPCRs and provide an alternative to biochemical assays for following signal transduction pathways from receptors at the cell surface to nuclear gene transcription in living cells (Hill *et al*., [@b16]). Here we have used an NFAT-luciferase reporter gene to investigate the impact of four representative RTKIs on VEGF~165~a- and VEGF~165~b-stimulated NFAT-luciferase activity in HEK-293 cells expressing human VEGFR2.

Methods
=======

Cell lines
----------

HEK-293 cells expressing the human VEGFR2 and an NFAT reporter gene were provided by Promega Corporation. The NFAT reporter gene contained an NFAT response element linked via a minimal promoter to the firefly luciferase gene luc2P containing a human sequence enriched in proline (P), glutamic acid (E), serine (S) and threonine (T) protein destabilization sequence (Voon *et al*., [@b29]). VEGFR2 NFAT cells were maintained in DMEM media supplemented with 10% FCS and 0.5% G418 in a humidified 5% CO~2~/95% air atmosphere at 37°C.

Measurement of VEGFR2-stimulated NFAT-reporter gene activity in HEK-293 cells
-----------------------------------------------------------------------------

VEGFR2 NFAT cells were seeded in a T75 flask at 5 × 10^6^ cells per flask using DMEM +10%FCS and incubated at 37°C in a 5% CO~2~/95% air atmosphere for 3 days until the cells were 100% confluent. On the fourth day, cells were washed with PBS and detached using 3 mL Versene® (ETDA 0.02% in PBS). Once cells had detached, 6 mL of DMEM +0.1%BSA was added and the cells were counted using a haemocytometer. Cells were centrifuged at 200× *g* for 5 min, resuspended in DMEM +0.1%BSA and seeded at a density of 4 × 10^4^ cells per well in 80 μL DMEM +0.1%BSA in white-sided, clear flat-bottomed 96-well plates (Greiner, Stonehouse, UK), which had been coated with 0.01 mg·mL^−1^ poly-D-lysine in PBS for 30 min and washed with DMEM. Cells were then incubated for 1 h in a humidified 5% CO~2~/95% air atmosphere at 37°C. RTKIs or vehicle control were added in 10 μL DMEM +0.1%BSA for 1 h prior to addition of VEGF~165~a or VEGF~165~b in 10 μL DMEM +0.1%BSA and the incubation was continued for a further 5 h (in a humidified 5% CO~2~/95% air atmosphere at 37°C). After the 5 h incubation, 100 μL ONE-Glo Luciferase Assay reagent was added to each well and luminescence was measured according to the manufacturer\'s instructions on a Topcount platereader (Perkin Elmer, Llantrisant, UK).

Data analysis
-------------

All data were fitted using non-linear regression in Prism 6 (GraphPad Software, San Diego, CA, USA). VEGF~165~a and VEGF~165~b concentration--response curves were fitted to the following equation:

Where *E*~max~ is the maximal response, and the EC~50~ is the molar concentration of agonist required to generate 50% of the *E*~max~. When investigating the effect of different concentrations of RTKI on concentration--response curves for VEGF~165~a, the data were also fitted to Equation [@b1] with parameters for either EC~50~ of *E*~max~ shared between all curves. A comparison of the extra sum of squares that resulted from the analysis with separate EC~50~ or *E*~max~ values (over that with one of the parameters shared) using the *F*-test (Prism 6) then allowed for statistical analysis of the difference between EC~50~ or *E*~max~ values.

Inhibition curves obtained with RTKIs in the presence of a fixed concentration of VEGF~165~a or VEGF~165~b were fitted to the following equation:

Where \[*A*\] is the concentration of RTKI and the *IC*~50~ is the molar concentration of ligand required to inhibit 50% of the response to VEGF.

Partial agonist concentration--response curves to VEGF~165~b were also fitted to the operational model of Black and Leff ([@b3]) using the following equation:

Where *E*~max~ is the maximal response of the system, \[*A*\] is the concentration of VEGF~165~b, *n* is the slope parameter, *K*~A~ is the dissociation constant of the agonist VEGF~165~b and τ is the transducer constant, which is a practical measure of efficacy. τ is the inverse of the fraction of receptors that must be occupied by agonist to obtain the half-maximal response. *E*~max~ was determined by simultaneously fitting Equation [@b1] to the concentration--response data for VEGF~165~a that were obtained in the same experiments as those for VEGF~165~b. *E*~max~ was shared between the two simultaneous fits.

Equation [@b3] was also used to simultaneously fit concentration--response curves to VEGF~165~a in the presence and absence of increasing concentrations of a define RTKI. In this case, *E*~max~, *n* and *K*~A~ (which in this case is the dissociation constant of VEGF~165~a) were shared between the simultaneous fits.

All data are presented as mean ± SEM. The *n* in the text refers to the number of separate experiments. Statistical significance was determined by Student\'s unpaired *t*-test or by one or two-way [anova]{.smallcaps} with Dunnett\'s *post hoc* analysis and *P* \< 0.05 was considered statistically significant.

Materials
---------

VEGF~165~a and VEGF~165~b were obtained from R&D systems (Abingdon, UK). Vandetanib, pazopanib, cediranib and sorafenib were supplied by Sequoia Research Products (Pangbourne, UK). The ONE-Glo™ Luciferase Assay System was obtained from Promega Corporation (Madison, WI, USA). Versene was obtained from Lonza (Basal, Switzerland). G418 was purchased from Life Technologies (Paisley, UK). All other chemicals and reagents were purchased from Sigma-Aldrich (Gillingham, UK).

Results
=======

VEGF~165~a-stimulated NFAT-luciferase production in intact cells
----------------------------------------------------------------

Incubation with VEGF~165~a produced a concentration-dependent (pEC~50~ 9.66 ± 0.05, *n* = 10) increase in NFAT-mediated luciferase production in HEK-293 cells expressing VEGFR2 that was 8.30 ± 0.85-fold (*n* = 10) over basal levels (Table [1](#tbl1){ref-type="table"}; Figure [1A](#fig01){ref-type="fig"} and [B](#fig01){ref-type="fig"}). The response to 1 nM VEGF~165~a was inhibited by the RTKI cediranib in intact HEK-293 cells in a concentration-dependent manner (Figure [1C](#fig01){ref-type="fig"}; Table [2](#tbl2){ref-type="table"}). The pIC~50~ obtained for cediranib (9.13; Figure [2A](#fig02){ref-type="fig"}, Table [2](#tbl2){ref-type="table"}) was in close agreement with that reported from binding studies with the purified VEGFR2 kinase domain (Davis *et al*., [@b7]). It was also noticeable that there was no marked inhibition by cediranib below basal levels at the highest concentration used (Figures [1C](#fig01){ref-type="fig"} and [2A](#fig02){ref-type="fig"}), suggesting that the ability of this RTKI to inhibit other tyrosine kinases (e.g. PDGFR-A, PDGFR-B and EGFR, Davis *et al*., [@b7]) did not significantly impact on the response observed. This was confirmed when the effect of cediranib was evaluated for its ability to inhibit basal NFAT-luciferase production (Figure [1D](#fig01){ref-type="fig"}). A significant inhibition (*P* \< 0.05; one way [anova]{.smallcaps}) of the small basal NFAT-luciferase response was only observed at concentrations of cediranib above 10 nM (Figure [1D](#fig01){ref-type="fig"}). Analysis of all five repeat experiments indicated that a significant inhibition of basal signalling was only obtained at the two highest concentrations used (*P* \< 0.05; one way [anova]{.smallcaps}; *n* = 5).

###### 

Concentration--response parameters for VEGF~165~a- and VEGF~165~b-stimulated NFAT-luciferase responses

               −Log EC~50~   *E*~max~ (% VEGF~165a~ max)   *n*
  ------------ ------------- ----------------------------- -----
  VEGF~165~a   9.66 ± 0.05   100                           10
  VEGF~165~b   9.21 ± 0.08   62.1 ± 1.2                    5

Values are mean ± SEM of *n* separate experiments. Each individual experiment was performed in quadruplicate.

![The effect VEGF~165~a on NFAT-mediated gene transcription in VEGFR2 NFAT cells. VEGFR2 NFAT cells were treated with VEGF~165~a (A and B) or cediranib +1 nM VEGF~165~a (C). Data are mean ± SEM from quadruplicate determinations in a single representative experiment that was repeated on five separate occasions (A and C). Normalized data from five repeat experiments expressed as a percentage of the response to 10 nM VEGF~165~a in each experiment (B). Effect of cediranib on basal NFAT-luciferase activity (D). Data are mean ± SEM from quadruplicate determinations in a single representative experiment that was repeated on five separate occasions. The histogram in (A) and (C) show the control response to 1 nM VEGF~165~a (A and C) and that to VEGF~165~a in the presence of the vehicle (containing DMSO) for the highest concentration of cediranib used in the competition experiment shown in (C).](bph0172-3141-f1){#fig01}

###### 

The effect of selected RTKIs on VEGF-stimulated firefly luciferase production in VEGFR2 NFAT cells

               Inhibition of 1 nM VEGF~165~a pIC~50~   *n*   Inhibition of 3 nM VEGF~165~b pIC~50~   n   Reported binding pK~D~ for purified kinase domain[\*](#tf2-2){ref-type="table-fn"}
  ------------ --------------------------------------- ----- --------------------------------------- --- ------------------------------------------------------------------------------------
  Cediranib    9.13 ± 0.01                             5     9.38 ± 0.07                             5   8.96
  Pazopanib    8.25 ± 0.03                             5     8.29 ± 0.10                             8   7.85
  Sorafenib    8.01 ± 0.06                             5     7.96 ± 0.04                             5   7.23
  Vandetanib   6.72 ± 0.03                             5     7.00 ± 0.04                             6   6.08

VEGFR2 NFAT cells were treated with each RTKI and either 1 nM VEGF~165~a or 3 nM VEGF~165~b. Data are mean ± SEM of *n* separate experiments. Each individual experiment was performed in quadruplicate. Individual fitted values for pIC~50~ values were obtained in each individual experiment and then analysed to provide mean ± SEM data provided here.

Values taken from Davis *et al*., [@b7].

![The effect of selected RTKIs on NFAT gene transcription stimulated by 1 nM VEGF~165~a. VEGFR2 NFAT cells were treated with (A) cediranib, (B) pazopanib, (C) vandetanib or (D) sorafenib. Data are mean ± SEM of five separate experiments. Data are expressed as a percentage of the response to 1 nM VEGF~165~a in the absence of RTKIs. Each individual experiment was performed in quadruplicate.](bph0172-3141-f2){#fig02}

Inhibition of 1 nM VEGF~165~a-stimulated NFAT-luciferase activity was also obtained with a second-class I RTKI (pazopanib, which has a different inhibitor selectivity profile compared with cediranib, e.g. FGFR1-3, PDGFRA/B, VEGFR1 and EGF; Davis *et al*., [@b7]) and with sorafenib and vandetanib (Figure [2](#fig02){ref-type="fig"}, Table [2](#tbl2){ref-type="table"}). All RTKIs tested produced pIC~50~ values, which were in agreement with those reported previously in binding studies on purified VEGFR2 kinase domains (Table [2](#tbl2){ref-type="table"}). As with cediranib, there was no marked inhibition below basal responses (Figure [2B](#fig02){ref-type="fig"}) with pazopanib (which is also a potent PDGFR inhibitor, Davis *et al*., [@b7]). In contrast, both sorafenib (−25.0 ± 2.6%, *n* = 5) and vandetanib (−23.0 ± 3.7%, *n* = 5) produced a small significant inhibition (*P* \< 0.05, paired *t*-test) below basal levels, which may reflect some interference with other tyrosine kinases at the higher concentrations required to inhibit VEGFR2 with these inhibitors.

VEGF binding to VEGFR2 requires Ig-like domains D2 and D3 in the extracellular portion of the receptor (Dosch and Ballmer-Hofer, [@b9]; Leppänen *et al*., [@b20]). In contrast, the kinase domain, which is the target for RTKIs lies within the intracellular portion of the receptor. As a consequence, the interaction between VEGF and RTKI in intact cells should show classical non-competitive interactions when concentration--response curves to VEGF~165~a are analysed in the presence of increasing concentrations of RTKIs. These data for VEGF-stimulated NFAT-luciferase production are shown in Figure [3](#fig03){ref-type="fig"} and Table [3](#tbl3){ref-type="table"}. All four inhibitors produced a significant (*P* \< 0.05) concentration-dependent reduction in the maximal response to VEGF~165~a (Table [3](#tbl3){ref-type="table"}). Analysis of all the individual experiments indicated that there was a small, but significant change (*P* \< 0.05) in EC~50~ at the highest concentrations of RTKIs used (Table [3](#tbl3){ref-type="table"}). However, global analysis of the combined data presented in Figure [3](#fig03){ref-type="fig"} indicated that there was only a significant difference in the EC~50~ values for cediranib (*P* \< 0.05). In contrast, there was a significant decrease in *E*~max~ with all four RTKIs (*P* \< 0.001; extra sum of squares *F*-test; Figure [3](#fig03){ref-type="fig"}).

![The effect of RTKIs on VEGF~165~a concentration--response curves. VEGFR2 NFAT cells were treated with (A) pazopanib, (B) vandetanib, (C) cediranib or (D) sorafenib for 1 h prior to the addition of increasing concentrations of VEGF~165~a. Data are mean ± SEM of five (A and B), six (C) or seven (D) replicate experiments. Each individual experiment was performed in quadruplicate. Global analysis of the combined data presented for each RTKI (A--D; extra sum of squares *F*-test) indicated that there was only a significant difference in the EC~50~ values for cetiranib (*P* \< 0.05). In contrast, there was a significant decrease in *E*~max~ with all four RTKIs (*P* \< 0001; Figure 3; extra sum of squares *F*-test).](bph0172-3141-f3){#fig03}

###### 

Effect of RTKIs on VEGF~165~a concentration--response parameters

  Vandetanib   Pazopanib                                      Cediranib                                     Sorafenib                                                                                                                                                                                                                                                        
  ------------ ---------------------------------------------- --------------------------------------------- ----------- ---------------------------------------------- --------------------------------------------- ----- ---------------------------------------------- ---------------------------------------------- ---- ---------------------------------------------- ---------------------------------------------
  0            9.90 ± 0.14                                    100.0                                         0           9.66 ± 0.11                                    100.0                                         0     9.68 ± 0.09                                    100.0                                          0    9.72 ± 0.06                                    100.0
  30           9.77 ± 0.10                                    81.0 ± 4.1                                    1           9.50 ± 0.09                                    85.2 ± 7.0                                    0.3   9.40 ± 0.10                                    64.8 ± 10.4[\*](#tf3-2){ref-type="table-fn"}   3    9.50 ± 0.05                                    70.1 ± 6.9[\*](#tf3-2){ref-type="table-fn"}
  100          9.75 ± 0.12                                    58.5 ± 5.7[\*](#tf3-2){ref-type="table-fn"}   3           9.43 ± 0.13                                    71.4 ± 5.2[\*](#tf3-2){ref-type="table-fn"}   1     9.28 ± 0.12                                    31.1 ± 6.6[\*](#tf3-2){ref-type="table-fn"}    10   9.33 ± 0.06[\*](#tf3-2){ref-type="table-fn"}   52.9 ± 5.1[\*](#tf3-2){ref-type="table-fn"}
  300          9.41 ± 0.14[\*](#tf3-2){ref-type="table-fn"}   29.5 ± 7.9[\*](#tf3-2){ref-type="table-fn"}   10          9.14 ± 0.16[\*](#tf3-2){ref-type="table-fn"}   32.8 ± 2.0[\*](#tf3-2){ref-type="table-fn"}   3     9.13 ± 0.18[\*](#tf3-2){ref-type="table-fn"}   8.8 ± 1.9[\*](#tf3-2){ref-type="table-fn"}     30   9.00 ± 0.13[\*](#tf3-2){ref-type="table-fn"}   18.9 ± 8.9[\*](#tf3-2){ref-type="table-fn"}

pEC~50~ and *E*~max~ values for VEGF~165~a obtained in the presence of increasing concentrations of four RTKIs.

*P* \< 0.05 compared with corresponding control in the absence of RTKI (one-way [anova]{.smallcaps}). Values are mean ± SEM from six (cediranib), five (pazopanib), seven (sorafenib) and five (vandetanib) separate experiments.

Pharmacological characteristics of the splice variant, VEGF~165~b, in HEK-293 cells
-----------------------------------------------------------------------------------

In the present study, VEGF~165~b produced a robust NFAT-luciferase response in HEK-293 cells expressing human VEGFR2 that accounted for 62.1% (Table [1](#tbl1){ref-type="table"}, Figure [4](#fig04){ref-type="fig"}) of the maximum response obtained with VEGF~165~a in the same experiments. The EC~50~ values were, however, very similar (Table [1](#tbl1){ref-type="table"}, Figure [4A](#fig04){ref-type="fig"}). Analysis of the concentration--response curves using the operational model of Black and Leff ([@b3]) for partial agonists indicated that the log *K*~A~ for VEGF~165~b was −8.83 ± 0.13 (*n* = 5) and the transducer constant **τ** was 1.65 ± 0.23 (*n* = 5). **τ** is a measure of agonist efficacy and represents the inverse of the fraction of receptors (60.1%) that must be occupied by agonist to obtain the half-maximal response (Black and Leff, [@b3]). The response to 3 nM VEGF~165~b was sensitive to inhibition by RTKIs with similar potencies to those obtained when VEGF~165~a was used as agonist (Figure [4B](#fig04){ref-type="fig"}; Table [2](#tbl2){ref-type="table"}).

![Characterization of the effect of VEGF~165~b on NFAT-luciferase repsonses. (A) A comparison of VEGF~165~a and VEGF~165~b concentration--response curves. (B) Inhibition of VEGF~165~b-stimulated NFAT-luciferase responses by cediranib. In (B), the concentration of VEGF~165~b was 3 nM. Data are mean ± SEM of five separate experiments. Four replicates were made for each condition in each individual experiment.](bph0172-3141-f4){#fig04}

Discussion
==========

VEGF receptors have been shown to activate several intracellular signalling pathways including PKC, PLCγ, MAPK and calcium-calcineurin (Suehiro *et al*., [@b28]). Calcineurin signalling activates NFAT transcription factors leading to the stimulation of gene transcription (Hill *et al*., [@b16]; Suehiro *et al*., [@b28]; Yang *et al*., [@b32]). Stimulation of PLCγ increases levels of inositol-1,4,5-trisphosphate (IP~3~) and diacyglycerol. IP~3~ then stimulates the release of intracellular calcium while diacylglycerol activates PKC. Increased intracellular calcium concentration stimulates calcineurin leading to the dephosphorylation of cytoplasmic NFAT transcription factors allowing them to translocate to the nucleus. In parallel, PKC activation results in the production of the AP-1 immediate early genes c-fos and c-jun. Once in the nucleus, NFAT binds with c-fos and c-jun to form a transcriptional complex capable of synergistically activating both the NFAT and the AP-1 response elements to stimulate gene expression (Masuda *et al*., [@b22]; Macian *et al*., [@b21]; Hill *et al*., [@b16]). In endothelial cells, VEGF treatment leads to NFAT nuclear localization and the expression of pro-angiogenic and pro-inflammatory genes (Suehiro *et al*., [@b28]; Yang *et al*., [@b32]). Furthermore, the calcineurin-NFAT pathway appears to be an important route for VEGF-mediated signalling (Suehiro *et al*., [@b28]; Yang *et al*., [@b32]). Here we have used a reporter gene containing the NFAT promoter coupled to the expression of firefly luciferase (Hill *et al*., [@b16]; Voon *et al*., [@b29]) to investigate in living cells the pharmacological characteristics of VEGF~165~a- and VEGF~165~b-induced gene expression in HEK-293 cell transfected with human VEGFR2.

Both VEGF~165~a and VEGF~165~b were able to produce a robust and potent stimulation of NFAT-mediated luciferase gene expression after 5 h of incubation. Both isoforms had very similar EC~50~ values that were in the nanomolar range (Table [1](#tbl1){ref-type="table"}). This is in keeping with previous reports that VEGF~165~b has a lower efficacy than VEGF~165~a for VEGFR2-mediated responses (Woolard *et al*., [@b30]; Cebe Suarez *et al*., [@b6]; Kawamura *et al*., [@b17]; Catena *et al*., [@b5]). The alternatively spliced variant VEGF~165~b was a partial agonist of NFAT-luciferase production eliciting a maximal response that was only 62% of that achieved by VEGF~165~a. Analysis of the VEGF~165~b concentration--response data using the operational model of Black and Leff ([@b3]) provides a means by which both the dissociation binding constant (*K*~A~) and the efficacy (in terms of the τ constant) of VEGF~165~b can be estimated. This produced an estimate for pK~A~ of VEGF~165~b at VEGFR2 (8.83) and a value of 1.65 for the efficacy parameter τ (indicating that 60.1% of receptors need to be occupied by VEGF~165~b in order to achieve 50% of the maximal cellular response). The similarity of EC~50~ values for the two VEGF isoforms, however, suggests that the relatively large response to VEGF~165~b compared with that seen in other studies (Cebe Suarez *et al*., [@b6]; Kawamura *et al*., [@b17]; Catena *et al*., [@b5]) is not a consequence of a large amplification of the signalling pathways to NFAT-mediated gene expression in these cells. Furthermore, previous work has suggested that VEGF~165~a and VEGF~165~b have the same binding affinities for VEGFR2 (Woolard *et al*., [@b30]; Cebe Suarez *et al*., [@b6]).

Interestingly, previous work has indicated that the extent to which VEGF~165~b can elicit responses may depend on the cellular context and the signalling cascade measured. Thus, while VEGF~165~b was a very weak agonist of MAPK and Akt phosphorylation in VEGFR2 transfected CHO cells, it was able to stimulate a robust MAPK and Akt phosphorylation in human microvascular endothelial cells (Woolard *et al*., [@b30]). Furthermore, signalling pathway differences in the relative efficacy of VEGF-A isoforms have been observed for the activation of VEGFR2-mediated responses (ERK1/2, p38 MAPK, Akt) in HUVECs by VEGF~165~a and VEGF~121~a (Fearnley *et al*., [@b10]). Previous studies, however, have largely been based on Western blot analysis, and it is clear that the NFAT-luciferase system reported here provides a powerful system for the quantitative evaluation of concentration--response relationships for drugs interacting with human VEGFR2 in living cells.

Four representative RTKIs (cediranib, pazopanib, vandetanib and sorafenib) were able to inhibit both VEGF~165~a- and VEGF~165~b-mediated NFAT-luciferase expression with similar potency, and yielded IC~50~ values that were similar to the *K*~D~ values reported from binding studies with purified VEGFR2 kinase domains (Davis *et al*., [@b7]). This similarity suggests that all four compounds readily cross the cell membrane in intact living cells. The target for VEGF binding within VEGFR2 is to domains D2 and D3 of the extracellular portion of the receptor (Dosch and Ballmer-Hofer, [@b9]; Leppänen *et al*., [@b20]). In contrast, RTKIs interact in various ways (depending on RTKI class) with the intracellular kinase domain of the receptor. As a consequence, the interaction between VEGF and RTKI in intact cells would be expected to show classical non-competitive interactions and lead to a marked change in the maximum response to VEGF~165~a with little impact on the EC~50~ value for the agonist. This is what was observed in the present study (Figure [3](#fig03){ref-type="fig"}). All four RTKIs produced a marked reduction in the *E*~max~ values for VEGF~165~a with only a small change in the pEC~50~ value. At the highest concentrations of RTKIs used, the pEC~50~ was generally between 9.00 and 9.14, which provides an indication of the PK~A~ for VEGF~165~a. Global analysis of the combined data shown in Figure [3](#fig03){ref-type="fig"} for each inhibitor (using the extra sum of squares *F*-test) indicated that it was only cediranib that had a significant difference in EC~50~ between the four sets of VEGF~165~a concentration--responses curves.

The non-competitive nature of the inhibition produced by RTKIs via the intracellular kinase domain, however, provided an opportunity to estimate the binding affinity of VEGF~165a~ by utilizing the operational model of Black and Leff ([@b3]). In this model, the transducer ratio tau (τ) is a measure of efficacy and reflects the ratio (total receptor number)/*K*~E~ where K~E~ describes the hyperbolic relationship in the system between the response and the concentration of agonist-receptor complexes. Receptor alkylation experiments have been used previously to reduce the number of binding sites as a way to obtain concentration--response relationships with different τ values, but with common values for *K*~E~, *E*~max~ and *K*~A~. Use of an RTKI targeted against VEGFR2 kinase activity is also a way of reducing τ values without changing the maximal capacity of the NFAT reporter gene system in the cells. In this case, the inhibition of the VEGFR2 kinase activity will interfere with signal transduction at the level of the receptor. This will effectively alter the *K*~E~ value and increase the concentration of agonist--receptor complexes needed to produce a function response. However, this analysis assumes that the RTKI has no allosteric effect on the binding affinity of VEGF~165~a. Thus, increasing concentrations of RTKIs should decrease the apparent efficacy of VEGF~165~a in this cellular system and reduce the transducer constant τ. All other parameters in terms of *K*~A~, *E*~max~ and should, however, remain unchanged.

If the concentration--response curves obtained with a given RTKI presented in Figure [3](#fig03){ref-type="fig"} are simultaneously analysed on this basis (with these assumptions), the following estimates of the pK~A~ value for VEGF~165~a are obtained: 8.9, 8.9, 9.4 and 9.0 (for the data sets obtained with cediranib, sorafenib, vandetanib and pazopanib respectively). The mean value obtained from this analysis for VEGF~165~a (8.9) is almost identical to that obtained for the partial agonist VEGF~165~b (8.8) in keeping with previous reports that their affinities are identical (Woolard *et al*., [@b30]; Cebe Suarez *et al*., [@b6]). Interestingly, vandetanib produced a higher estimate for the pK~A~ of VEGF~165~a than that obtained with the other RTKIs. This suggests that the nature of the interaction of vandetanib with VEGFR2 has produced an allosteric conformational change in the ligand binding site for VEGF~165~a and altered its affinity for VEGF~165~a.

It should be noted that all four RTKIs produced a small inhibition of the responses to VEGF~165~a and VEGF~165~b below basal levels (Figure [2](#fig02){ref-type="fig"}; Figure [4B](#fig04){ref-type="fig"}). A similar effect has been seen with other RTKs (Forsell *et al*., [@b13]) and has been ascribed to constitutive activity of the receptor. However, in the present study, the effect is likely to be due to inhibition of other tyrosine kinases within this cell line. The effect of cediranib on basal NFAT signalling seen in Figure [1D](#fig01){ref-type="fig"} is consistent with this, particularly at the higher concentration used. Thus, the potency of cediranib for inhibition of VEGF-stimulated NFAT signalling and basal NFAT signalling, respectively, are quite different (Figure [1C](#fig01){ref-type="fig"} and [D](#fig01){ref-type="fig"}). Thus, although the major effects of RTKIs reported here are consequences of an interaction with VEGFR2, it must be remembered that interference with other tyrosine kinase signalling cascades is possible at higher concentrations of these inhibitors.

In summary, the present study has shown that the VEGFR2 NFAT-luciferase reporter gene system provides a robust way to investigate, in a quantitative manner, the interaction of drugs (both agonists and RTKIs) with VEGFR2 in an intact cellular environment. Quantitative pharmacological analysis of the interaction of these drugs with VEGFR2 in living cells has provided important insights into the relative affinity and efficacy of VEGF~165~a and VEGF~165~b for activation of the calcineurin--NFAT signalling pathway by this tyrosine kinase receptor. This opens the way for similar quantitative approaches to be used to evaluate affinity and efficacy measures for different VEGF isoforms in mediating responses via other signalling cascades. This should shed light on the potential for VEGFR2 agonists to bias signalling to particular intracellular pathways.
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